Netley Dsouza, MD
Family Medicine · Tucson, AZNPI 1447299193
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,138 of the $6,542 with a category attached, or 78.5%. It is spread thinly across 33 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,764 and has fallen 96.0% since, to $150 in 2025. Among family medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$869
- Novo Nordisk$807
- GSK$583
- AstraZeneca$454
- C. R. Bard, Inc. & Subsidiaries$387
- Sanofi$365
- plus $3K from 27 others
What the payments were for
- Consulting fees$5378%
- Speaking & faculty fees$84713%
- Food & beverage$5,13879%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $869 |
| Novo Nordisk | 64 | $807 |
| GSK | 16 | $583 |
| AstraZeneca | 10 | $454 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $387 |
| Sanofi | 2 | $365 |
| Johnson & Johnson | 23 | $329 |
| Pfizer | 34 | $315 |
| Amarin Pharma, Inc. | 13 | $290 |
| Lilly USA, LLC | 11 | $257 |
| Boehringer Ingelheim | 18 | $249 |
| Amgen(2 entities) | 13 | $238 |
| Sanofi-aventis U.S. LLC | 12 | $177 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $157 |
| Jazz Pharmaceuticals Inc. | 1 | $150 |
| Merck | 9 | $136 |
| Radius Health, Inc. | 5 | $127 |
| Boston Scientific | 4 | $85 |
| Strongbridge US Inc. | 4 | $68 |
| Arbor Pharmaceuticals, Inc. | 4 | $61 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Abbott | 2 | $40 |
| Astellas Pharma US Inc | 3 | $38 |
| Nevro Corp. | 1 | $24 |
| Novartis | 2 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Medtronic | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,542 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 47 | $50,013 |
| RybelsusSemaglutide | 18 | $46,363 |
| EliquisApixaban | 28 | $42,183 |
| OzempicSemaglutide | 21 | $38,450 |
| Zileuton ErZileuton | 12 | $32,204 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $23,994 |
| FarxigaDapagliflozin Propanediol | 20 | $22,044 |
| JanuviaSitagliptin Phosphate | 19 | $20,019 |
| MounjaroTirzepatide | 17 | $17,413 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,258 |
| Atorvastatin Calcium | 322 | $7,677 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,544 |
| Losartan Potassium | 199 | $2,836 |
| Rosuvastatin Calcium | 101 | $2,548 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $2,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $807 | $84,81439 claims |
| Boehringer IngelheimJardiance | $249 | $50,01347 claims |
| PfizerEliquis | $315 | $42,18328 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $583 | $34,25147 claims |
| AstraZenecaFarxiga, Symbicort | $454 | $26,58935 claims |
| MerckJanuvia | $136 | $20,01919 claims |
| Lilly USA, LLCMounjaro | $257 | $17,41317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Tucson
- Katherine WilsonTucson$29K
- Kimy CharaniTucson$21K
- Mark GrantTucson$21K
- Christian MoherTucson$13K
- Dean WrightTucson$12K
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.